ENTPD1
Description
The ENTPD1 (ectonucleoside triphosphate diphosphohydrolase 1) is a protein-coding gene located on chromosome 10.
ENTPD1, also known as CD39 (Cluster of Differentiation 39), is a cell surface enzyme that breaks down nucleotides. It converts ATP (or ADP) to adenosine monophosphate (AMP), which is then converted to adenosine by another enzyme, CD73. This process plays a role in inflammation, as adenosine has anti-inflammatory effects. ENTPD1 also contributes to the function of regulatory T cells (Tregs), which help to suppress the immune system. Mutations in ENTPD1 can cause autosomal recessive spastic paraplegia 64 (SPG64). High expression and activity of CD39 and CD73 on cancer cells can prevent the immune system from inhibiting the progression of cancer.
ENTPD1, also known as CD39, is an enzyme that hydrolyzes both di- and triphosphate nucleotides (NDPs and NTPs), converting them to nucleotide monophosphates (NMPs) in two successive steps. It plays a role in regulating extracellular nucleotide levels, and its activity contributes to the control of inflammation and platelet aggregation. By hydrolyzing proinflammatory ATP and platelet-activating ADP to AMP, ENTPD1 helps to block platelet aggregation and maintain blood flow.
ENTPD1 is also known as ATP-DPH, ATPDase, CD39, NTPDase-1, SPG64.
